BioSpace News Archive

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, announced today the Phase 2b trial of MIN-117 in adult patients suffering from moderate to severe major depressive disorder (MDD) and presenting with symptoms of anxious distress failed to meet its primary and key secondary endpoints.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at upcoming conferences

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended September 30, 2019.

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion of a human bioavailability study of CMIO-OLNZ, a 7-day matrix transdermal delivery system of olanzapine for the treatment of poly ADP ribose polymerase (PARP) inhibitor induced nausea and vomiting (PIINV) (the “Study”).

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today unveiled its latest solution for decentralized clinical trials from Covance to help transform the conduct of hybrid and virtual trials.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), announced today that the Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company a 5-year contract,

Seattle Genetics, Inc. will host a conference call and webcast on Thursday, December 19, 2019 to discuss the U.S. Food and Drug Administration approval of PADCEVTM.

Revive Therapeutics Ltd., a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that all the resolutions put forward by the Company at its annual general meeting of shareholders held on December 18, 2019 were approved at the AGM.

Monopar Therapeutics Inc. announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share.